Icrucumab (Not yet branded)
Immunotherapy
Description
Icrucumab is a monoclonal antibody that targets the VEGFR-1 (vascular endothelial growth factor receptor-1) pathway for the treatment of metastatic colorectal cancer. This anti-angiogenic agent works by blocking blood vessel formation that tumors require for growth and metastasis. It has been evaluated in combination therapy regimens for patients with advanced colorectal cancer who have progressed on standard treatments.
Mechanism of Action
Icrucumab binds specifically to VEGFR-1 (Flt-1), blocking the interaction between VEGF ligands and this receptor. By inhibiting VEGFR-1 signaling, the drug disrupts tumor angiogenesis and reduces the formation of new blood vessels that feed tumor growth and enable metastatic spread.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.